DNA polymerase theta (Polθ): a novel candidate for targeted cancer therapy.
Polθ is a promising target for cancer therapy due to its overexpression in tumors, but further clinical validation is needed.
Where it sits
this study against the rest of the ara 290 corpusSummary and findings
The review discusses the role of DNA polymerase theta (Polθ) in DNA repair, particularly in cancer, where it is overexpressed. It highlights the potential of Polθ as a therapeutic target and reviews current strategies and clinical trials. The paper also addresses limitations and future research directions.
Abstract
DNA double-strand breaks (DSBs) are the most severe DNA damage, and defective repair can lead to apoptosis or malignant transformation. DSBs are mainly repaired by nonhomologous end joining (NHEJ) and homologous recombination (HR), while microhomology-mediated end joining (MMEJ) serves as a backup pathway. Since DNA polymerase theta (Polθ) is essential for MMEJ, this pathway is also named Polθ-mediated end joining. Polθ is barely expressed in normal tissues but overexpressed in many cancers, making it a promising therapeutic target. In recent years, Polθ inhibitors and related therapeutic strategies have emerged rapidly, with clinical trials underway. This review summarizes the structure, function and expression of Polθ in tumorigenesis, highlights synthetic lethal strategies, drug development and clinical translation, and discusses current limitations and future directions for cancer research.
Background
DNA double-strand breaks (DSBs) are critical lesions that can lead to cell death or cancer if not properly repaired. Traditional repair mechanisms include nonhomologous end joining (NHEJ) and homologous recombination (HR), with microhomology-mediated end joining (MMEJ) as a backup. DNA polymerase theta (Polθ) is crucial for MMEJ and is minimally expressed in normal tissues but overexpressed in various cancers, making it a potential target for cancer therapy. Understanding Polθ's role in tumorigenesis and its therapeutic potential is important for developing new cancer treatments.
Methods
This paper is a review article that compiles and synthesizes existing research on the structure, function, and expression of DNA polymerase theta (Polθ) in cancer. It discusses synthetic lethal strategies, drug development, and clinical translation related to Polθ. The review does not involve new experimental data or specific methodologies.
Results
The review highlights that Polθ is overexpressed in many cancers, making it a promising target for therapeutic intervention. It discusses the emergence of Polθ inhibitors and related strategies, as well as ongoing clinical trials. The paper also identifies current limitations in the research and suggests future directions for investigation.
Interpretation
The review suggests that targeting Polθ could be a viable strategy for cancer therapy, given its overexpression in tumors and minimal presence in normal tissues. However, the clinical significance of these findings remains to be validated through ongoing and future trials. The lack of new experimental data in the review limits its immediate applicability to clinical practice.
Key findings
- Polθ is essential for microhomology-mediated end joining (MMEJ).
- Polθ is overexpressed in many cancers but barely expressed in normal tissues.
- Polθ inhibitors and therapeutic strategies are rapidly emerging.
- Clinical trials targeting Polθ are currently underway.
Limitations
- Review article, no new data.
- Focuses on existing literature and ongoing trials.
- No quantitative findings reported.